Compare Repligen Corporation Common Stock (RGEN) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Stryker Corporation — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while Stryker Corporation trades at $282 (market cap $108.38B). The key difference: Stryker Corporation is far larger — about 9.7× Repligen Corporation Common Stock's market cap, and Stryker Corporation pays a 1.25% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Stryker Corporation for 22 Days on average.
| RGEN | SYK | |
|---|---|---|
Market Cap | $11.14B | $108.38B |
Volume | 1,259,263 | 2,068,363 |
Sector | Health | Health |
52-Week High | $194.57 | $388.35 |
52-Week Low | $102.87 | $269.75 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $11.02B | $119.84B |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Stryker (SYK) trades at $282.63, showing minimal daily movement. The stock exhibits a neutral technical stance with mixed moving averages and oscillators. Fundamentally, SYK maintains strong profitability with a 14.43% net income margin and 16.51% ROE, though a P/E of 29.28 suggests a premium valuation. Recent news highlights ongoing legal scrutiny over a manufacturing issue disclosed in September 2026, which caused a significant price drop. Q3 2026 earnings are anticipated on October 29, 2026, following a mix of beats and misses in prior quarters.
The outlook for SYK is cautiously optimistic, supported by analyst consensus with a $365.89 price target and no sell ratings. Investment appeal lies in its solid cash flow and market position, but risks include legal investigations and persistent operational challenges. The stock's near-term direction will likely hinge on Q3 earnings results and clarity on the manufacturing issue resolution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
